PATHOLOGIC PROCESSES
Clinical trials for PATHOLOGIC PROCESSES explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC PROCESSES trials appear
Sign up with your email to follow new studies for PATHOLOGIC PROCESSES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug could slash surgeries for rare airway disease
Disease control OngoingThis phase II trial tests whether bevacizumab, a drug that blocks blood vessel growth, can lengthen the time between surgeries for adults with recurrent respiratory papillomatosis (RRP), a rare condition causing wart-like growths in the airways. Participants receive 11 doses of t…
Matched conditions: PATHOLOGIC PROCESSES
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug hope for scleroderma patients with lung complications
Disease control OngoingThis study tests an experimental drug called ifetroban in 34 adults with a severe form of scleroderma (diffuse cutaneous systemic sclerosis) or scleroderma-related lung disease (pulmonary arterial hypertension). The main goal is to see if the drug is safe and whether it can impro…
Matched conditions: PATHOLOGIC PROCESSES
Phase: PHASE2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Heart monitor after ablation may cut AF time
Disease control OngoingThis study tests whether using an implantable heart monitor (or a wearable patch) to detect atrial fibrillation early after catheter ablation can reduce the total time spent in AF. About 120 people with paroxysmal or persistent AF will be monitored for 15 months. The goal is to s…
Matched conditions: PATHOLOGIC PROCESSES
Phase: NA • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Promising ITP drug trial pulled before it even started
Disease control TerminatedThis study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…
Matched conditions: PATHOLOGIC PROCESSES
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 26, 2026 18:23 UTC